What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

Gynecologic oncology ·Vol. 105 ·No. 1 ·2007-04-00 ·Pages 3-6

Han ES, Monk BJ

Abstract

暂无摘要

MeSH Terms

Angiogenesis Inhibitors/adverse effects,therapeutic use Antibodies, Monoclonal/adverse effects,therapeutic use Antibodies, Monoclonal, Humanized Bevacizumab Clinical Trials, Phase II as Topic Female Humans Intestinal Perforation/chemically induced,therapy Neovascularization, Pathologic/drug therapy Ovarian Neoplasms/blood supply,drug therapy

Chemicals

Angiogenesis Inhibitors Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Bevacizumab

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Han Ernest S

Monk Bradley J

Article Info

Journal

Gynecologic oncology

Abbr.

Gynecol Oncol

ISSN

0090-8258

DOI

10.1016/j.ygyno.2007.01.038

Published

2007-04-00

Pages

3-6

Language

English

Region

United States

NLM ID

0365304

Subset

External Links

PubMed source DOI: 10.1016/j.ygyno.2007.01.038 View journal details

Analysis Services

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

Contact

WeChat Official Account